Document Detail

Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the clinical trials.
MedLine Citation:
PMID:  21534885     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: There is a need for new and improved treatments for type 2 diabetes. Glucagon-like peptide 1 (GLP-1) is a gut hormone that stimulates insulin secretion and the levels of GLP-1 can be increased by inhibiting DPP-4. Sitagliptin is one of the DDP-4 inhibitors used to increase the levels of GLP-1. Exenatide is an agonist at the GLP-1 receptors, which is resistant to breakdown and has a longer action than GLP-1.
AREAS COVERED: This review compares the clinical trials of sitagliptin and exenatide once weekly in the treatment of type 2 diabetes. Only peer-reviewed trials listed on PubMed were included.
EXPERT OPINION: Both sitagliptin and exenatide once weekly are capable of reducing HbA1c and plasma glucose levels, but exenatide once weekly is more potent than sitagliptin and this may lead to different roles for these agents in the treatment of type 2 diabetes.
Sheila A Doggrell
Related Documents :
21106865 - Incorporating incretin-based therapies into clinical practice: differences between gluc...
11914735 - Mice with targeted gene disruptions or gene insertions for diabetes research: problems,...
21768545 - Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing...
22096315 - α-glucosidase inhibitors from plants: a natural approach to treat diabetes.
24521245 - Lixisenatide resensitizes the insulin-secretory response to intravenous glucose challen...
15551295 - Postprandial glucose monitoring in type 1 diabetes mellitus: use of a continuous subcut...
Publication Detail:
Type:  Journal Article; Review     Date:  2011-05-03
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  12     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2011 Sep 
Date Detail:
Created Date:  2011-08-08     Completed Date:  2012-02-03     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  2055-67     Citation Subset:  IM    
Queensland University of Technology, Discipline of Medical Sciences, Faculty of Science and Technology, Brisbane, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Clinical Trials as Topic
Diabetes Mellitus, Type 2 / drug therapy*
Dipeptidyl-Peptidase IV Inhibitors / administration & dosage
Drug Administration Schedule
Hypoglycemic Agents / administration & dosage
Peptides / administration & dosage*
Pyrazines / administration & dosage*
Randomized Controlled Trials as Topic
Triazoles / administration & dosage*
Venoms / administration & dosage*
Reg. No./Substance:
0/Dipeptidyl-Peptidase IV Inhibitors; 0/Hypoglycemic Agents; 0/Peptides; 0/Pyrazines; 0/Triazoles; 0/Venoms; 141732-76-5/exenatide; QFP0P1DV7Z/sitagliptin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of maternal exposure to ozone on reproductive outcome and immune, inflammatory, and allergic ...
Next Document:  Antiretroviral use during pregnancy for treatment or prophylaxis.